Brentuximab vedotin in the treatment of CD30+ PTCL | Blood | American Society of Hematology
You do not currently have access to this content.
Related Articles
Is inflammation key in Kaposi sarcoma?
The mortality from herpesvirus–associated malignancies, such as Kaposi sarcoma (KS), may primarily be due to cellular inflammasome activation and systemic
Red blood cells: more than bags of hemoglobin
In this issue of Blood, Jiang et al1 suggest an intriguing role for red blood cells (RBCs) in regulating hemostasis through both platelet-dependent and -in
A randomized trial of blood donor iron repletion on red cell quality for transfusion and donor cognition and well-being
Key Points. Blood donation–induced iron deficiency did not significantly affect red blood cell quality for transfusion.Iron repletion of iron-deficient blo
A rare glimpse of Fessas bodies in a patient with β-thalassemia major postsplenectomy
Kevin Shopsowitz, Habib Moshref Razavi; A rare glimpse of Fessas bodies in a patient with β-thalassemia major postsplenectomy. Blood 2024; 144 (14): 1543. doi: https://doi.org/10.1182/blood.2024025262…
Permissible HLA mismatches in 9/10 unrelated donor pediatric stem cell transplants using HLA-EMMA: an EBMT Inborn Errors Working Party study
Key PointsUsing HLA-EMMA, a subgroup of 9/10 HLA-mismatched transplants with a permissible mismatch can be identified with favorable EFS.Permissibly mismat
Classification and risk stratification in T-lineage acute lymphoblastic leukemia
Cure rates for patients with acute lymphoblastic leukemia (ALL) have improved markedly in recent decades, in part due to risk stratification incorporating
Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange
Key PointCaplacizumab with immunosuppression, but without additional TPE, is an effective and safe treatment strategy for acute iTTP.
Notes From the Hill: Embracing Change and Becoming Unstoppable | ASH Clinical News | American Society of Hematology
The American Society of Hematology (ASH) selected Shakira J. Grant, MBBS, MSCR, as the 2023-2024 ASH Congressional Fellow. The Congressional Fellow program aims to connect…
Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy
Key PointsPatients with limited (<5 disease sites) pre-CART B-cell NHL are at high risk of local relapse/progression.BRT before CART for patients with R